ISPOR - P39 Patient-Reported Outcomes As Endpoint in Oncology Trials: An Analysis of FDA and EMA Claims

Full Text

P39 Patient-Reported Outcomes As Endpoint in Oncology Trials: An Analysis of FDA and EMA Claims

Abstract

Authors

C. Desvignes-Gleizes N.G. Kraft S. Desruol-Allardin S. Bothorel R. Sherafat

Back to Volume 26, Supplemental Issue 6S

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now